Beam Therapeutics
Climate Impact & Sustainability Data (2022)
Reporting Period: 2022
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Risk of severe adverse effects associated with use of the chemotherapeutic drug busulfan for pretransplant myeloablative conditioning in autologous hematopoietic stem cell transplant (HSCT) gene therapy for hemoglobinopathies including sickle cell disease (SCD).
Mitigation Strategies
- Development of a nongenotoxic investigational therapy for hemoglobinopathies that combines multi-plex base edited engineered HSCs (eHSCs) with antibody-based conditioning.